Involvement of Embryo-Derived and Monocyte-Derived Intestinal Macrophages in the Pathogenesis of Inflammatory Bowel Disease and Their Prospects as Therapeutic Targets

• Published in: International journal of molecular sciences 2024-01, Vol.25 (2), p.690
• Main Authors: Zuo, Shujun, Jiang, Liping, Chen, Luying, Wang, Weikang, Gu, Jintao, Kuai, Jiajie, Yang, Xuezhi, Ma, Yang, Han, Chenchen, Wei, Wei
• Format: Article
• Language: English
• Subjects: Adalimumab; Anti-Inflammatory Agents; Antigen presentation; Bacteria; Balsalazide; Chemokines; Colon; Corticosteroids; Cytokines; Embryonic development; Fibroblasts; Health aspects; Homeostasis; Humans; Immunosuppressive agents; Inflammation; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - etiology; inflammatory immunity; intestinal homeostasis; intestinal macrophages; Kinases; Ligands; Macrophages; Mesalamine; Microbiota (Symbiotic organisms); Microorganisms; Monocytes; Nervous system; Pathogens; Remission (Medicine); Smooth muscle
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25020690

Inflammatory bowel disease (IBD) is a group of intestinal inflammatory diseases characterized by chronic, recurrent, remitting, or progressive inflammation, which causes the disturbance of the homeostasis between immune cells, such as macrophages, epithelial cells, and microorganisms. Intestinal macrophages (IMs) are the largest population of macrophages in the body, and the abnormal function of IMs is an important cause of IBD. Most IMs come from the replenishment of blood monocytes, while a small part come from embryos and can self-renew. Stimulated by the intestinal inflammatory microenvironment, monocyte-derived IMs can interact with intestinal epithelial cells, intestinal fibroblasts, and intestinal flora, resulting in the increased differentiation of proinflammatory phenotypes and the decreased differentiation of anti-inflammatory phenotypes, releasing a large number of proinflammatory factors and aggravating intestinal inflammation. Based on this mechanism, inhibiting the secretion of IMs' proinflammatory factors and enhancing the differentiation of anti-inflammatory phenotypes can help alleviate intestinal inflammation and promote tissue repair. At present, the clinical medication of IBD mainly includes 5-aminosalicylic acids (5-ASAs), glucocorticoid, immunosuppressants, and TNF-α inhibitors. The general principle of treatment is to control acute attacks, alleviate the condition, reduce recurrence, and prevent complications. Most classical IBD therapies affecting IMs function in a variety of ways, such as inhibiting the inflammatory signaling pathways and inducing IM2-type macrophage differentiation. This review explores the current understanding of the involvement of IMs in the pathogenesis of IBD and their prospects as therapeutic targets.